A Henry Ford Health System study shows the controversial anti-malaria drug hydroxychloroquine helps lower the death rate of COVID-19 patients, the Detroit-based health system said Thursday.Some entities in Michigan refuse to use the anti-malarial drug, the article reports.
The study analyzed 2,541 patients hospitalized among the system’s six hospitals between March 10 and May 2 and found 13% of those treated with hydroxychloroquine died while 26% of those who did not receive the drug died.
We attribute our findings that differ from other studies to early treatment, and part of a combination of interventions that were done in supportive care of patients, including careful cardiac monitoring.
Later ... Writing for Just the News, Sheryl Attkisson reports this HFHS research has been published in the peer-refereed International Journal of Infectious Diseases. For those who don't know, "peer-reviewed" means we should pay additional attention to the findings. Scientists in the field not involved in doing the research have examined the report and find it worthy.
